Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-500608-23-00 | Other Identifier | EU CT |
Not provided
Not provided
Not provided
Strategic considerations
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine how telisotuzumab vedotin affects the disease state in adult participants with previously untreated participants with MET amplified non-squamous NSCLC. Change in disease activity will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of MET amplified non-squamous NSCLC. Participants receive intravenously (IV) infused of telisotuzumab vedotin. Approximately 70 adult participants with previously untreated MET amplified locally advanced/metastatic non-squamous NSCLC will be enrolled in the study in approximately 110 sites worldwide.
Participants will receive IV telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Telisotuzumab Vedotin | Experimental | Participants will receive telisotuzumab vedotin every 2 weeks until meeting study drug discontinuation criteria. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Telisotuzumab Vedotin | Biological | Intravenous (IV) Infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate (ORR) as Assessed by an Independent Central Review (ICR) | ORR was defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 as assessed by ICR. | Up to approximately 1.5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Response (DoR) | DoR was defined for confirmed responders as the time from the initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1, or death from any cause. | Up to approximately 1.5 years |
| Disease Control Rate (DCR) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cancer and Blood Speciality Clinic - Los Alamitos /ID# 251671 | Los Alamitos | California | 90720-3309 | United States | ||
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
A total of 9 participants were enrolled and received at least 1 dose of study drug.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Telisotuzumab Vedotin | Participants received telisotuzumab vedotin by intravenous (IV) infusion every 2 weeks until they met study drug discontinuation criteria. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 7, 2023 | Oct 13, 2025 |
Not provided
Not provided
Not provided
Not provided
Not provided
DCR was defined as the percentage of participants with best overall response of confirmed CR or confirmed PR, or stable disease (SD) for at least 12 weeks following first dose of study drug, based on RECIST, version 1.1. |
| Up to approximately 1.5 years |
| Progression Free Survival (PFS) Per ICR | PFS was defined as the time from the participant's first dose of study drug to the first occurrence of radiographic progression based on RECIST, version 1.1 or death from any cause. | Up to approximately 1.5 years |
| Overall Survival (OS) | OS was defined as the time from participant's first dose of study drug to the event of death from any cause. | Up to approximately 1.5 years |
| Change From Baseline in Cough as Measured by the Cough Item of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13) | The cough item of the EORTC QLQ-LC13 was reported on a 0 to 100 scale, with higher scores representing worse health outcomes with increasing symptom levels or impacts. A negative change from baseline value indicated reduction (i.e. improvement) in symptoms. | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
| Change From Baseline in Pain as Measured by the Pain in Chest Item of the EORTC QLQ-LC13 | The pain in chest item of the EORTC QLQ-LC13 was reported on a 0 to 100 scale, with higher scores representing worse health outcomes with increasing symptom levels or impacts. A negative change from baseline value indicated reduction (i.e. improvement) in symptoms. | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
| Change From Baseline in Dyspnea as Measured by the Dyspnea Item of the EORTC QLQ-LC13 | The dyspnea item of the EORTC QLQ-LC13 was reported on a 0 to 100 scale, with higher scores representing worse health outcomes with increasing symptom levels or impacts. A negative change from baseline value indicated reduction (i.e. improvement) in symptoms. | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
| Change From Baseline in Quality of Life as Measured by the Global Health Status/Quality of Life Domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). | The Global Health Status/Quality of Life Domain of the EORTC QLQ-C30 was reported on a scale of 0 to 100, with higher scores indicating better global health status/functioning and a positive change from baseline indicating improvement. | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
| Valley Medical Center /ID# 251880 |
| Renton |
| Washington |
| 98055-5738 |
| United States |
| Monash Health - Monash Medical Centre /ID# 247679 | Clayton | Victoria | 3168 | Australia |
| CHU Lille - Hôpital Albert Calmette /ID# 246263 | Lille | Hauts-de-France | 59037 | France |
| Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267 | Bron | Rhone | 69500 | France |
| Centre Jean Perrin /ID# 246268 | Clermont-Ferrand | 63011 | France |
| Asklepios Fachkliniken Muenchen-Gauting /ID# 248082 | Gauting | 82131 | Germany |
| Meir Medical Center /ID# 243208 | Kfar Saba | Central District | 4428164 | Israel |
| Rambam Health Care Campus /ID# 246781 | Haifa | H_efa | 3109601 | Israel |
| Hadassah Medical Center-Hebrew University /ID# 243298 | Jerusalem | Jerusalem | 91120 | Israel |
| The Chaim Sheba Medical Center /ID# 243207 | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Rabin Medical Center /ID# 248631 | Petah Tikva | 4941492 | Israel |
| Duplicate_Fondazione IRCCS San Gerardo dei Tintori /ID# 247584 | Monza | Monza E Brianza | 20900 | Italy |
| Istituto di Candiolo Fondazione del Piemonte per l'Oncologia IRCCS /ID# 248329 | Candiolo | Torino | 10060 | Italy |
| IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 247585 | Rome | 00144 | Italy |
| National Cancer Center Hospital East /ID# 250317 | Kashiwa-shi | Chiba | 277-8577 | Japan |
| Duplicate_National Hospital Organization Kyushu Cancer Center /ID# 250714 | Fukuoka | Fukuoka | 811-1395 | Japan |
| Hokkaido University Hospital /ID# 250316 | Sapporo | Hokkaido | 060-8648 | Japan |
| Osaka International Cancer Institute /ID# 251507 | Osaka | Osaka | 541-8567 | Japan |
| Shizuoka Cancer Center /ID# 251752 | Sunto-gun | Shizuoka | 411-8777 | Japan |
| National Cancer Center Hospital /ID# 250319 | Chuo-ku | Tokyo | 104-0045 | Japan |
| Keimyung University Dongsan Hospital /ID# 247371 | Daegu | Gyeongsangbuk-do | 42601 | South Korea |
| Pusan National University Yangsan Hospital /ID# 248489 | Yangsan | Gyeongsangnam-do | 50612 | South Korea |
| Chungbuk National University Hospital /ID# 248405 | Cheongju-si | North Chungcheong | 28644 | South Korea |
| Samsung Medical Center /ID# 248407 | Seoul | Seoul Teugbyeolsi | 06351 | South Korea |
| Kaohsiung Chang Gung Memorial Hospital /ID# 248143 | Kaohsiung City | Kaohsiung | 833 | Taiwan |
| Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 248144 | Kaohsiung City | 807 | Taiwan |
| National Cheng Kung University Hospital /ID# 248142 | Tainan | 704 | Taiwan |
| Linkou Chang Gung Memorial Hospital /ID# 248145 | Taoyuan City | 333 | Taiwan |
| Received at Least 1 Dose of Study Drug |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Telisotuzumab Vedotin | Participants received telisotuzumab vedotin by IV infusion every 2 weeks until they met study drug discontinuation criteria. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Objective Response Rate (ORR) as Assessed by an Independent Central Review (ICR) | ORR was defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 as assessed by ICR. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. | Posted | Number | 95% Confidence Interval | percentage of participants | Up to approximately 1.5 years |
|
|
| |||||||||||||||||||||||||
| Secondary | Duration of Response (DoR) | DoR was defined for confirmed responders as the time from the initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1, or death from any cause. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. Here, "Overall number of participants analyzed" represents participants evaluable for this outcome measure with CR or PR. | Posted | Median | 95% Confidence Interval | months | Up to approximately 1.5 years |
|
| ||||||||||||||||||||||||||
| Secondary | Disease Control Rate (DCR) | DCR was defined as the percentage of participants with best overall response of confirmed CR or confirmed PR, or stable disease (SD) for at least 12 weeks following first dose of study drug, based on RECIST, version 1.1. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. | Posted | Number | 95% Confidence Interval | percentage of participants | Up to approximately 1.5 years |
|
| ||||||||||||||||||||||||||
| Secondary | Progression Free Survival (PFS) Per ICR | PFS was defined as the time from the participant's first dose of study drug to the first occurrence of radiographic progression based on RECIST, version 1.1 or death from any cause. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. | Posted | Median | 95% Confidence Interval | months | Up to approximately 1.5 years |
|
| ||||||||||||||||||||||||||
| Secondary | Overall Survival (OS) | OS was defined as the time from participant's first dose of study drug to the event of death from any cause. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. | Posted | Median | 95% Confidence Interval | months | Up to approximately 1.5 years |
|
| ||||||||||||||||||||||||||
| Secondary | Change From Baseline in Cough as Measured by the Cough Item of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module 13 (EORTC QLQ-LC13) | The cough item of the EORTC QLQ-LC13 was reported on a 0 to 100 scale, with higher scores representing worse health outcomes with increasing symptom levels or impacts. A negative change from baseline value indicated reduction (i.e. improvement) in symptoms. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" is the number of participants evaluable for this outcome measure, and "Number analyzed" is the number of participants evaluated at each time point. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
|
| ||||||||||||||||||||||||||
| Secondary | Change From Baseline in Pain as Measured by the Pain in Chest Item of the EORTC QLQ-LC13 | The pain in chest item of the EORTC QLQ-LC13 was reported on a 0 to 100 scale, with higher scores representing worse health outcomes with increasing symptom levels or impacts. A negative change from baseline value indicated reduction (i.e. improvement) in symptoms. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" is the number of participants evaluable for this outcome measure, and "Number analyzed" is the number of participants evaluated at each time point. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
|
| ||||||||||||||||||||||||||
| Secondary | Change From Baseline in Dyspnea as Measured by the Dyspnea Item of the EORTC QLQ-LC13 | The dyspnea item of the EORTC QLQ-LC13 was reported on a 0 to 100 scale, with higher scores representing worse health outcomes with increasing symptom levels or impacts. A negative change from baseline value indicated reduction (i.e. improvement) in symptoms. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" is the number of participants evaluable for this outcome measure, and "Number analyzed" is the number of participants evaluated at each time point. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
|
| ||||||||||||||||||||||||||
| Secondary | Change From Baseline in Quality of Life as Measured by the Global Health Status/Quality of Life Domain of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). | The Global Health Status/Quality of Life Domain of the EORTC QLQ-C30 was reported on a scale of 0 to 100, with higher scores indicating better global health status/functioning and a positive change from baseline indicating improvement. | The efficacy evaluable analysis set included all participants who received at least 1 dose of study drug. Here, "Overall Number of Participants Analyzed" is the number of participants evaluable for this outcome measure, and "Number analyzed" is the number of participants evaluated at each time point. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 30, 32 |
|
|
All-cause mortality and adverse event tables include events reported from the start of safety data collection (Day 1) to the end of the study. The median time on follow-up was 14.3 months.
All-cause mortality and adverse events: all participants who received at least 1 dose of study drug.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Telisotuzumab Vedotin | Participants received telisotuzumab vedotin by IV infusion every 2 weeks until they met study drug discontinuation criteria. | 4 | 9 | 3 | 9 | 9 | 9 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| DIARRHOEA | Gastrointestinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| INTESTINAL OBSTRUCTION | Gastrointestinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| DISEASE PROGRESSION | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA 27.1 | Systematic Assessment |
| |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PNEUMONITIS | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANAEMIA | Blood and lymphatic system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| LEUKOCYTOSIS | Blood and lymphatic system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| NEUTROPENIA | Blood and lymphatic system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| HYPERTHYROIDISM | Endocrine disorders | MedDRA 27.1 | Systematic Assessment |
| |
| KERATITIS | Eye disorders | MedDRA 27.1 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| CONSTIPATION | Gastrointestinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| NAUSEA | Gastrointestinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| ASTHENIA | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| DISEASE PROGRESSION | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| FATIGUE | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| MEDICAL DEVICE PAIN | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| OEDEMA PERIPHERAL | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 27.1 | Systematic Assessment |
| |
| CHOLESTASIS | Hepatobiliary disorders | MedDRA 27.1 | Systematic Assessment |
| |
| ORAL FUNGAL INFECTION | Infections and infestations | MedDRA 27.1 | Systematic Assessment |
| |
| LIGAMENT SPRAIN | Injury, poisoning and procedural complications | MedDRA 27.1 | Systematic Assessment |
| |
| ALANINE AMINOTRANSFERASE INCREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| ASPARTATE AMINOTRANSFERASE INCREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| BLOOD ALKALINE PHOSPHATASE INCREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| BLOOD GLUCOSE INCREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| BLOOD TESTOSTERONE DECREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| C-REACTIVE PROTEIN INCREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| LYMPHOCYTE COUNT DECREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| NEUTROPHIL COUNT INCREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| WEIGHT DECREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| WHITE BLOOD CELL COUNT DECREASED | Investigations | MedDRA 27.1 | Systematic Assessment |
| |
| DECREASED APPETITE | Metabolism and nutrition disorders | MedDRA 27.1 | Systematic Assessment |
| |
| HYPOALBUMINAEMIA | Metabolism and nutrition disorders | MedDRA 27.1 | Systematic Assessment |
| |
| HYPOKALAEMIA | Metabolism and nutrition disorders | MedDRA 27.1 | Systematic Assessment |
| |
| NEUROPATHY PERIPHERAL | Nervous system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PERIPHERAL SENSORY NEUROPATHY | Nervous system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PRESYNCOPE | Nervous system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| TASTE DISORDER | Nervous system disorders | MedDRA 27.1 | Systematic Assessment |
| |
| COUGH | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| HAEMOPTYSIS | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PNEUMONITIS | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PULMONARY HAEMORRHAGE | Respiratory, thoracic and mediastinal disorders | MedDRA 27.1 | Systematic Assessment |
| |
| PRURITUS | Skin and subcutaneous tissue disorders | MedDRA 27.1 | Systematic Assessment |
| |
| RASH | Skin and subcutaneous tissue disorders | MedDRA 27.1 | Systematic Assessment |
|
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Medical Services | AbbVie | 800-633-9110 | abbvieclinicaltrials@abbvie.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 25, 2023 | Oct 13, 2025 | SAP_001.pdf |
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000626235 | telisotuzumab vedotin |
Not provided
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|